IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1316.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Smartphone-based device could provide rapid, low-cost molecular tumor diagnosis
A device developed by Massachusetts General Hospital investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology.
National Institutes of Health, US Department of Defense

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 13-Apr-2015
Annals of Internal Medicine
Task Force weighs evidence on diabetes screening; more research news in Annals of Internal Medicine
Articles featured in the April 14, 2015, issue of Annals of Internal Medicine include 'Task Force weighs evidence on diabetes screening', 'Survey: Proposed regulations may contradict patient attitudes towards medical research' and 'Cancer experts: Too many patients being screened, diagnosed, and treated.'

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 13-Apr-2015
Journal of Clinical Investigation
U-M researchers find new gene involved in blood-forming stem cells
Research led by the University of Michigan Life Sciences Institute has identified a gene critical to controlling the body's ability to create blood cells and immune cells from blood-forming stem cells -- known as hematopoietic stem cells.
Sidney Kimmel Cancer Research Foundation, University of Michigan Comprehensive Cancer Center, D. Dan and Betty Kahn Foundation, National Institutes of Health, University of Michigan Medical Scientist Training Program, Center for Organogenesis, and others

Contact: Ian Demsky
idemsky@umich.edu
734-647-9837
University of Michigan

Public Release: 13-Apr-2015
Cancer Cell
Promising developments in tackling resistance to blood cancer drugs
A drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukemias and non-Hodgkin lymphomas in clinical trials later this year. Targeted drugs made from engineered immune proteins -- called monoclonal antibodies -- have revolutionized treatment for several types of cancer in recent years.
Leukaemia & Lymphoma Research, Cancer Research UK

Contact: Charles Elder
c.elder@soton.ac.uk
44-023-805-98933
University of Southampton

Public Release: 13-Apr-2015
PLOS ONE
Brazilian study suggests adjustments on the treatment of cancer patients with pneumonia
Pneumonia is the most frequent type of infection in cancer patients and it is associated with high mortality rates. Brazilian researchers analyzed the factors associated with severe pneumonia in hospitalized cancer patients and suggest that personalized treatment protocols can reduce mortality in this population. Their work indicates that the standard broad-spectrum antibiotic treatment used by physicians worldwide may not be the better choice for this group.

Contact: Jorge Salluh
jorgesalluh@gmail.com
D'Or Institute for Research and Education

Public Release: 13-Apr-2015
Cancer
HPV vaccination of adolescent boys may be cost-effective for preventing oropharyngeal cancer
A new study indicates that vaccinating 12-year-old boys against the humanpapilloma virus may be a cost-effective strategy for preventing oropharyngeal squamous cell cancer, a cancer that starts at the back of the throat and mouth, and involves the tonsils and base of the tongue.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Molecular signature for outcomes of triple negative breast cancer
Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. In a new study published in the journal Proceedings of the National Academy of Sciences, researchers at Huntsman Cancer Institute and the University of Utah have identified a molecular mechanism that triple negative breast cancer cells use to survive and grow.
National Institutes of Health, Huntsman Cancer Foundation, Cancer Center Support Grant, China Scholarship Council Grant

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Pitt cancer virology team reveals new pathway that controls how cells make proteins
A serendipitous combination of technology and scientific discovery, coupled with a hunch, allowed University of Pittsburgh Cancer Institute researchers to reveal a previously invisible biological process that may be implicated in the rapid growth of some cancers.
National Institutes of Health, NIH/National Cancer Institute

Contact: Allison Hydzik
Hydzikam@upmc.edu
University of Pittsburgh Schools of the Health Sciences

Public Release: 13-Apr-2015
Nature Cell Biology
Heart cells regenerated in mice
Weizmann Institute research gets mouse heart cells to take a step backwards so they can be renewed.

Contact: Yael Edelman
yael.edelman@weizmann.ac.il
Weizmann Institute of Science

Public Release: 13-Apr-2015
Nature Medicine
Researchers identify drug target for ATRA, the first precision cancer therapy
Cancerous tumors have the unique ability to activate alternative pathways to evade targeted therapy. They also contain cancer stem cells that can make them more aggressive and drug-resistant. Now researchers in the Cancer Research Institute at Beth Israel Deaconess Medical Center have identified a drug target that can address both of these challenges in two cancer types.

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center

Public Release: 13-Apr-2015
Oncogene
U-M researchers find protein that may signal more aggressive prostate cancers
University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.

Contact: Laura Bailey
baileylm@umich.edu
734-647-1848
University of Michigan

Public Release: 10-Apr-2015
Journal of the National Cancer Institute
Telomeres and cancer mortality: The long and the short of it
Telomeres are short stretches of repeated nucleotides that protect the ends of chromosomes. In somatic cells, these protective sequences become shorter with each cellular replication until a critical length is reached, which can trigger cell death.

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Oxford University Press USA

Public Release: 9-Apr-2015
Cell Reports
Researchers find new approach to treat drug-resistant HER2-positive breast cancer
Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the therapy. Using human cell lines of the HER2-positive breast cancer subtype, researchers from the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center have detailed the surprising ways in which resistance manifests and how to defeat it before it happens.
National Institutes of Health, Susan G. Komen Foundation, University Cancer Research Fund at University of North Carolina at Chapel Hill

Contact: Mark Derewicz
mark.derewicz@unchealth.unc.edu
919-923-0959
University of North Carolina Health Care

Public Release: 9-Apr-2015
JAMA Oncology
Axillary lymph node evaluation performed frequently in ductal carcinoma in situ
Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with localized cancer undergoing breast-conserving surgery, according to a study published online by JAMA Oncology.

Contact: Lucky Tran
lt2549@columbia.edu
212-305-3689
The JAMA Network Journals

Public Release: 9-Apr-2015
Environmental Health Perspectives
Increased levels of radon in Pennsylvania homes correspond to onset of fracking
Johns Hopkins Bloomberg School of Public Health researchers say that levels of radon in Pennsylvania homes -- where 42 percent of readings surpass what the US government considers safe -- have been on the rise since 2004, around the time that the fracking industry began drilling natural gas wells in the state.
NIH/National Institute of Environmental Health Sciences

Contact: Barbara Benham
bbenham1@jhu.edu
410-614-6029
Johns Hopkins University Bloomberg School of Public Health

Public Release: 9-Apr-2015
Journal of Pediatrics
A downward trend for new cases of pediatric melanoma
Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years. Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has been increasing. In a new study scheduled for publication in The Journal of Pediatrics, researchers found that the incidence of pediatric melanoma in the United States actually has decreased from 2004-2010.

Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences

Public Release: 9-Apr-2015
Cell
Stem cell disease model clarifies bone cancer trigger
Using induced pluripotent stem cells (iPSCs), a team led by Mount Sinai researchers has gained new insight into genetic changes that may turn a well known anti-cancer signaling gene into a driver of risk for bone cancers.
National Institutes of Health, Empire State Stem Cell Fund, University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund, National Breast Cancer Foundation

Contact: Renatt Brodsky
renatt.brodsky@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 9-Apr-2015
Molecular Cell
Study revises theory of how PTEN, a critical tumor suppressor, shuts off growth signals
From a team at CSHL, new evidence contradicting prior beliefs about how the protein PTEN -- one of the most important of the body's tumor suppressors -- works; specifically, how it is recruited to particular locations in our cells where pro-growth signals need to be shut off. It could help scientists design more effective drugs to counteract cancer's hallmark trait, uncontrolled cellular growth.
American Cancer Society, Pershing Square Sohn Foundation, US Department of Defense, National Institutes of Health, Robertson Research Fund of Cold Spring Harbor Laboratory

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory

Public Release: 9-Apr-2015
Developmental Cell
Golgi trafficking controlled by G-proteins
A family of proteins called G proteins are a recognized component of the communication system the human body uses to sense hormones and other chemicals in the bloodstream and to send messages to cells. In work that further illuminates how cells work, researchers at University of California, San Diego School of Medicine have discovered a new role for G proteins that may have relevance to halting solid tumor cancer metastasis.
National Institutes of Health, National Science Council of Taiwan, and American Heart Association

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 9-Apr-2015
ACS Chemical Biology
Breakthrough finds molecules that block previously 'undruggable' protein tied to cancer
University of Kansas findings on HuR, an 'oncoprotein,' hold promise for treating every type of cancer tested, including cancers of the colon, prostate, breast, brain, ovaries, pancreas and lung.

Contact: Brendan M Lynch
brendan@ku.edu
785-864-8855
University of Kansas

Public Release: 9-Apr-2015
New England Journal of Medicine
New Waldenstrom's drug shows sustained benefit at two years
Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years.
Pharmacyclics and Janssen Pharmaceuticals

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 9-Apr-2015
Cell
Review highlights potential of cancer immunotherapy plus targeted therapy
The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests 'we are finally poised to deliver curative therapies to cancer patients,' researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 9-Apr-2015
Nature Communications
Epigenomic changes play an important role during the progression of melanoma
KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures. Melanoma, a type of skin cancer, is notoriously quick to metastasize and responds poorly to existing cancer treatments. In their study, published in Nature Communications, the researchers report a significant step forward in the characterization and potential treatment of melanoma.

Contact: Katrien Bollen
news@kuleuven.be
KU Leuven

Public Release: 9-Apr-2015
British Journal of Cancer
York scientists lead study on new treatment for prostate cancer
Scientists at the University of York have discovered a potential new treatment for prostate cancer using low temperature plasmas.
Engineering and Physical Sciences Research Council , Wellcome Trust, Yorkshire Cancer Research

Contact: Saskia Angenent
saskia.angenent@york.ac.uk
44-019-043-23918
University of York

Public Release: 9-Apr-2015
Nature Communications
UTSW researchers lead collaborative charge to uncover genetic diversity of pancreatic cancer
A genetic analysis led by UT Southwestern Medical Center researchers suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment. The findings support a precision approach to treating pancreatic cancer, the fourth most deadly cancer for both men and women.
NIH/National Cancer Institute, Cancer Prevention and Research Institute of Texas

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Showing releases 1001-1025 out of 1316.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases

     

 

EurekAlert!